Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar 17;10:14.
doi: 10.1186/1471-2318-10-14.

Effects of Ginkgo Biloba in Dementia: Systematic Review and Meta-Analysis

Affiliations
Free PMC article
Review

Effects of Ginkgo Biloba in Dementia: Systematic Review and Meta-Analysis

Stefan Weinmann et al. BMC Geriatr. .
Free PMC article

Abstract

Background: The benefit of Ginkgo biloba has been discussed controversially. The aim of this review was to assess the effects of Ginkgo biloba in Alzheimer's disease as well as vascular and mixed dementia covering a variety of outcome domains.

Methods: We searched MEDLINE, EMBASE, the Cochrane databases, CINAHL and PsycINFO for controlled trials of ginkgo for Alzheimer's, vascular or mixed dementia. Studies had to be of a minimum of 12 weeks duration with at least ten participants per group. Clinical characteristics and outcomes were extracted. Meta-analysis results were expressed as risk ratios or standardized mean differences (SMD) in scores.

Results: Nine trials using the standardized extract EGb761(R) met our inclusion criteria. Trials were of 12 to 52 weeks duration and included 2372 patients in total. In the meta-analysis, the SMDs in change scores for cognition were in favor of ginkgo compared to placebo (-0.58, 95% confidence interval [CI] -1.14; -0.01, p = 0.04), but did not show a statistically significant difference from placebo for activities in daily living (ADLs) (SMD = -0.32, 95% CI -0.66; 0.03, p = 0.08). Heterogeneity among studies was high. For the Alzheimer subgroup, the SMDs for ADLs and cognition outcomes were larger than for the whole group of dementias with statistical superiority for ginkgo also for ADL outcomes (SMD = -0.44, 95% CI -0.77; -0.12, p = 0.008). Drop-out rates and side effects did not differ between ginkgo and placebo. No consistent results were available for quality of life and neuropsychiatric symptoms, possibly due to the heterogeneity of the study populations.

Conclusions: Ginkgo biloba appears more effective than placebo. Effect sizes were moderate, while clinical relevance is, similar to other dementia drugs, difficult to determine.

Figures

Figure 1
Figure 1
Flow chart of study identification and selection.
Figure 2
Figure 2
ITT/LOCF change scores for cognition outcomes (ADAS-cog, SKT) by individual trial and pooled standardized mean difference compared with placebo.
Figure 3
Figure 3
ITT/LOCF change scores for activities of daily living outcomes by individual trial and pooled standardized mean difference compared with placebo.

Similar articles

See all similar articles

Cited by 60 articles

See all "Cited by" articles

References

    1. DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets. 2000;1:25–58. doi: 10.2174/1389450003349380. - DOI - PubMed
    1. McCarney R, Fisher P, Iliffe S, van Haselen R, Griffin M, van der Meulen MJ. Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry. 2008;23:1222–1230. doi: 10.1002/gps.2055. - DOI - PubMed
    1. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300:2253–2262. doi: 10.1001/jama.2008.683. - DOI - PMC - PubMed
    1. Schneider LS. Ginkgo biloba extract and preventing Alzheimer disease. JAMA. 2008;300:2306–2308. doi: 10.1001/jama.2008.675. - DOI - PubMed
    1. Ernst E. A comment on Ginkgo biloba for mild to moderate dementia in a community setting by McCarney et al. Int J Geriatr Psychiatry. 2009;24:215–216. doi: 10.1002/gps.2171. - DOI - PubMed

MeSH terms

Feedback